| Derrick Cripps Gale, MD | |
|
4063 W 12600 S, Riverton, UT 84096-7302 | |
| (801) 328-2522 | |
| (801) 533-0589 |
| Full Name | Derrick Cripps Gale |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 11 Years |
| Location | 4063 W 12600 S, Riverton, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548695729 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | R6005 (Texas) | Secondary |
| 207Y00000X | Otolaryngology | 2013019934 (Missouri) | Secondary |
| 207Y00000X | Otolaryngology | 11131583-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lone Peak Hospital | Draper, UT | Hospital |
| Riverton Hospital | Riverton, UT | Hospital |
| Salt Lake Regional Medical Center | Salt lake city, UT | Hospital |
| Park City Hospital | Park city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Ear Nose And Throat Specialists Llc | 8022901610 | 22 |
News Archive
Officials say the moves would save the agency $58 million next year by changing how much it pays for some services and requiring agencies to prove their effectiveness.
ViroXis Corporation today announced that the US Food and Drug Administration (FDA) granted approval for the Company's investigational new drug (IND) application and planned clinical development of a drug substance derived from East Indian Sandalwood oil (EISO) for the topical treatment of Human Papilloma Virus (HPV), common warts of the skin.
Johannes Gutenberg University Mainz (JGU) has received EUR 900,000 for three years to investigate, jointly with the Institute of Molecular Biology (IMB), how gene regulation affects evolution and development.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of gastric cancers.
› Verified 5 days ago
| Entity Name | Intermountain Ear Nose And Throat Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487764411 PECOS PAC ID: 8022901610 Enrollment ID: O20040206000267 |
News Archive
Officials say the moves would save the agency $58 million next year by changing how much it pays for some services and requiring agencies to prove their effectiveness.
ViroXis Corporation today announced that the US Food and Drug Administration (FDA) granted approval for the Company's investigational new drug (IND) application and planned clinical development of a drug substance derived from East Indian Sandalwood oil (EISO) for the topical treatment of Human Papilloma Virus (HPV), common warts of the skin.
Johannes Gutenberg University Mainz (JGU) has received EUR 900,000 for three years to investigate, jointly with the Institute of Molecular Biology (IMB), how gene regulation affects evolution and development.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of gastric cancers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Derrick Cripps Gale, MD 756 E 12200 S, Draper, UT 84020-9724 Ph: (801) 328-2522 | Derrick Cripps Gale, MD 4063 W 12600 S, Riverton, UT 84096-7302 Ph: (801) 328-2522 |
News Archive
Officials say the moves would save the agency $58 million next year by changing how much it pays for some services and requiring agencies to prove their effectiveness.
ViroXis Corporation today announced that the US Food and Drug Administration (FDA) granted approval for the Company's investigational new drug (IND) application and planned clinical development of a drug substance derived from East Indian Sandalwood oil (EISO) for the topical treatment of Human Papilloma Virus (HPV), common warts of the skin.
Johannes Gutenberg University Mainz (JGU) has received EUR 900,000 for three years to investigate, jointly with the Institute of Molecular Biology (IMB), how gene regulation affects evolution and development.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of gastric cancers.
› Verified 5 days ago
Kevin Gilbert, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3723 W 12600 S, Suite 270b, Riverton, UT 84065 Phone: 801-285-4636 Fax: 801-285-4741 |